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Virtual adherens junctions
 
he textbook model of adherens
junctions has been exploded, or
severed, by Bill Weis, Soichiro
Yamada, Frauke Drees, Sabine Pokutta,
and W. James Nelson (Stanford Univer-
sity School of Medicine, Stanford, CA).
There is no direct link, they say, between
cadherin, via 
 
 
 
- and 
 
 
 
-catenin, to actin.
Weis’s original goal was ambi-
tious—a structural understanding of
adherens junctions. First came biochem-
istry. “It was only when we attempted to
reconstitute [the junctions],” he says,
“that we found that nobody had actually
done it before.” The textbook model
“was all based on binary interactions.”
The group now reports that 
 
 
 
-
catenin can either bind as a monomer to
 
 
 
-catenin and thus cadherin, or bind as a
homodimer to actin. But the binding
events are mutually exclusive so there is
no direct link from cadherin to actin.
Consistent with this, cadherins and actin
have very different dynamics.
Weis stresses that their two model
systems—clustered soluble fragments of
T
 
cadherin and membrane patches—are something less than a full-blown
adherens junctions. But such imprecision may be reasonable. In cells,
says Weis, although “there is certainly local [cadherin] clustering, I don’t 
 
Sending the advance party for metastases
 
umor cells induce other cells to act as trailblazers, say
Rosandra Kaplan, Rebecca Riba, Shahin Rafii, David
Lyden (Weill-Cornell, New York, NY), and col-
leagues. Those cells set up remote sites to which the tumor
cells can subsequently metastasize.
The trailblazers are bone marrow–derived cells (BMDCs)
that were earlier implicated in building blood vessels in estab-
lished tumors. When Kaplan saw the cells in metastases she
thought it was the same story. “For a long time we thought the
tumor cells got there and then brought the bone marrow cells
afterwards,” she says. But careful examination showed that,
both in mice and humans, the BMDCs showed up several days
before the first tumor cells. Interfering with the trailblazing
BMDCs prevented metastasis.
The group now thinks that growth factors from the tumors
have two distinct activities. They coax BMDCs out of the bone
marrow and into the circulation. And they induce fibroblasts
in other tissues to proliferate and make fibronectin. These fibro-
blast actions in turn attract the fibronectin-binding BMDCs,
which settle into their niche and start producing other factors
that attract the tumor cells.
T
 
think there’s precise geometry.”
In the dimeric state 
 
 
 
-catenin
inhibits actin polymerization by
Arp2/3, perhaps favoring formin’s
ability to create stable actin cables
over Arp2/3
 
 
 
s ability to promote protru-
sive actin branching. The membrane
patches did not, however, reconstitute
assembly of actin filaments, suggest-
ing that other proteins are missing.
These other proteins may link actin to
other membrane proteins, or they
may reinforce the actin-modifying
behavior of 
 
 
 
-catenin.
“People are very intrigued and
excited” by the new results, says Weis.
But the new textbook is clearly a work in
progress. One of the biggest mysteries is
how a system with no direct linkages
generates force during morphogenesis.
“Maybe all you need to do is to organize
the gel state of actin correctly, and that
organization will support the mechanical
function of the junction,” says Weis. But
“with constriction, you clearly need to
be linked to something.” 
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 -Catenin doesn’t link cadherin to actin (top) but does 
inhibit actin polymerization by Arp2/3 (bottom).
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This rather complex dance “is very logical,” says Lyden.
“Tissue regeneration is happening all the time: you need to make
new blood vessels all the time; you need to heal wounds all the
time.” The tumor, he thinks, is inducing remote sites to act as if
they are wounded or inflamed, thus recruiting the BMDCs as heal-
ers. The BMDCs need to recruit yet other cells to complete the
healing, yet in the process they pull the tumor cells into the mix.
The molecular details thus far consist of a specific receptor
(VEGFR1) and integrin (the fibronectin ligand VLA-4) on the
BMDCs. Kaplan and Lyden are now defining the profile of
factors made by different tumors in the hopes that this will be
predictive of future metastatic sites. 
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BMDCs (green) arrive early (left), preparing the way for tumor cells (red).
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